Natalizumab ( Tysabri ) Reported To Be a Safe and Effective Therapy for Pediatric Multiple Sclerosis
October 1, 2015 A new study recently published in the journal BMC Neurology revealed that natalizumab (TYSABRI) is a safe…
Possible JC Virus Vaccination Offers Important Implications for MS Treatment
Two studies recently published in the journal Science Translational Medicine, revealed a possible new vaccine treatment for JC virus with important…
Stuart Schlossman
New Mouse Model Better Represents JC Virus That Infects MS Patients
Posted by: Maureen Newman November 24, 2014 Researchers in the laboratory of Steve Goldman, MD, PhD, Co-Director of University…
Stuart Schlossman
Orphan Drug Designation Granted to Treatment for Rare Multiple Sclerosis Drug Complication
The Food and Drug Administration granted Orphan Drug Designation to Inhibikase Therapeutics’, Inc. lead product, IkT-001Pro (imatinib), to treat progressive multifocal leukoencephalopathy(PML). According…
Stuart Schlossman
Rare Brain Infection Death Spurs FDA To Update Warning Label for MS Drug
Posted by: Anna Tan, RN November 26, 2014 The US Food and Drug Administration has just issued a report warning the general public and…
Stuart Schlossman
Smoking Ups Natalizumab Neutralizing Antibodies in MS
Sue Hughes – October 03, 2014 BOSTON — Smoking appears to increase the likelihood of developing neutralizing antibodies to natalizumab (Tysabri, Biogen Idec),…
Stuart Schlossman
Multiple Sclerosis Symptom Recrudescence at the End of the Natalizumab Dosing Cycle
Volume 16, Issue 2 (Summer (2014) Article Citation:John N. Ratchford, Regina Brock-Simmons, Amanda Augsburger, Sonya U. Steele, Kristie Mohn, Mandi Rhone,…
Stuart Schlossman
Tysabri Protects Against Relapse in Multiple Sclerosis, According To Study
According to a study published in JAMA Neurology, multiple sclerosis patients are greatly benefited by Biogen Idec’s Tysabri (natalizumab) and tend to relapse…
Stuart Schlossman
To Stay, or Not to Stay, on Natalizumab in MS
Pauline Anderson June 02, 2014 DALLAS — Switching to fingolimod (Gilenya, Novartis) or an injectable therapy after 2 years of treatment with…
Stuart Schlossman
Biogen Idec Investigates Tysabri in Secondary-Progressive Multiple Sclerosis Patients
Biogen Idec is currently sponsoring a clinical trial evaluating its therapy Tysabri (natalizumab) in patients with secondary-progressive multiple sclerosis. Although relapse-remitting multiple…
Stuart Schlossman
